Efficacy and safety of midostaurin in advanced systemic mastocytosis Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Leukemia, Mast-Cell
  • Mastocytosis, Systemic
  • Staurosporine

abstract

  • In this open-label study, midostaurin showed efficacy in patients with advanced systemic mastocytosis, including the highly fatal variant mast-cell leukemia. (Funded by Novartis Pharmaceuticals and others; ClinicalTrials.gov number, NCT00782067.).

publication date

  • June 30, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1513098

PubMed ID

  • 27355533

Additional Document Info

start page

  • 2530

end page

  • 41

volume

  • 374

number

  • 26